This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Peláez, T.
Right arrow Articles by Bouza, E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Peláez, T.
Right arrow Articles by Bouza, E.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, March 2005, p. 1157-1159, Vol. 49, No. 3
0066-4804/05/$08.00+0     doi:10.1128/AAC.49.3.1157-1159.2005
Copyright © 2005, American Society for Microbiology. All Rights Reserved.

In Vitro Activity of Ramoplanin against Clostridium difficile, Including Strains with Reduced Susceptibility to Vancomycin or with Resistance to Metronidazole

T. Peláez,1* L. Alcalá,1 R. Alonso,1 A. Martín-López,1 V. García-Arias,1 M. Marín,1 and E. Bouza1

Department of Clinical Microbiology and Infectious Diseases, Hospital General Universitario "Gregorio Marañón," Madrid, Spain1

Received 2 May 2004/ Returned for modification 11 July 2004/ Accepted 17 November 2004

We evaluated the in vitro activity of ramoplanin, an antimicrobial compound that inhibits cell wall synthesis by acting at the level of lipid intermediate formation, against Clostridium difficile. We included strains with reduced susceptibilities to vancomycin (vancomycin-intermediate [Vani] strains) or with resistance to metronidazole (Mtzr), in order to assess the potential utility of ramoplanin for the treatment of C. difficile-associated diarrhea. We tested the activity of ramoplanin against a total of 105 nonduplicate clinical isolates of toxigenic C. difficile, including 8 Vani isolates and 6 Mtzr isolates, obtained from our laboratory. Ramoplanin was active against all strains tested at concentrations ranging from 0.03 to 0.5 µg/ml (MICs at which 50 and 90% of isolates were inhibited, 0.25 µg/ml; geometric mean MIC, 0.22 µg/ml). All isolates, independently of their levels of susceptibility to vancomycin or metronidazole, were considered susceptible to ramoplanin (MICs, ≤0.5 µg/ml).

* Corresponding author. Mailing address: Servicio de Microbiología Clínica y Enfermedades Infecciosas, Hospital General Universitario "Gregorio Marañón," C/ Dr. Esquerdo 46, 28007, Madrid, Spain. Phone: 34-1-5868453. Fax: 34-1-5044906. E-mail: terepelaez{at}teleline.es.

Antimicrobial Agents and Chemotherapy, March 2005, p. 1157-1159, Vol. 49, No. 3
0066-4804/05/$08.00+0     doi:10.1128/AAC.49.3.1157-1159.2005
Copyright © 2005, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • Williams, O. M., Spencer, R. C. (2009). The management of Clostridium difficile infection. Br Med Bull 0: ldp021v1-ldp021 [Abstract] [Full Text]  
  • Monaghan, T, Boswell, T, Mahida, Y R (2009). Recent advances in Clostridium difficile-associated disease. Postgrad. Med. J. 85: 152-162 [Abstract] [Full Text]  
  • Monaghan, T, Boswell, T, Mahida, Y R (2008). Recent advances in Clostridium difficile-associated disease. Gut 57: 850-860 [Abstract] [Full Text]  
  • Halsey, J. (2008). Current and future treatment modalities for Clostridium difficile-associated disease. Am J Health Syst Pharm 65: 705-715 [Abstract] [Full Text]  
  • Mutlu, E., Wroe, A. J., Sanchez-Hurtado, K., Brazier, J. S., Poxton, I. R. (2007). Molecular characterization and antimicrobial susceptibility patterns of Clostridium difficile strains isolated from hospitals in south-east Scotland. J Med Microbiol 56: 921-929 [Abstract] [Full Text]  
  • Odou, M.-F., Muller, C., Calvet, L., Dubreuil, L. (2007). In vitro activity against anaerobes of retapamulin, a new topical antibiotic for treatment of skin infections. J Antimicrob Chemother 59: 646-651 [Abstract] [Full Text]  
  • Surowiec, D., Kuyumjian, A. G, Wynd, M. A, Cicogna, C. E (2006). Past, Present, and Future Therapies for Clostridium difficile-Associated Disease. The Annals of Pharmacotherapy 40: 2155-2163 [Abstract] [Full Text]  
  • Aspevall, O., Lundberg, A., Burman, L. G., Akerlund, T., Svenungsson, B. (2006). Antimicrobial Susceptibility Pattern of Clostridium difficile and Its Relation to PCR Ribotypes in a Swedish University Hospital.. Antimicrob. Agents Chemother. 50: 1890-1892 [Abstract] [Full Text]  
  • Freeman, J., Baines, S. D., Jabes, D., Wilcox, M. H. (2005). Comparison of the efficacy of ramoplanin and vancomycin in both in vitro and in vivo models of clindamycin-induced Clostridium difficile infection. J Antimicrob Chemother 56: 717-725 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»